Novo Nordisk Ends Development of NN9828, Shifts Focus to Pandemic Initiatives 0 30.10.2020 03:00 Feedity.com Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes. Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
